Neurogene Inc. is advancing its Phase 1/2 clinical trial for NGN-401, a gene therapy for Rett syndrome in female pediatric patients.

Molecular Templates highlighted the promising results of their monotherapy drug candidate, MT-6402, particularly in patients with head and neck cancer.

The Phase 1b clinical trial for a novel antidepressant, VLS-01, developed by atai Life Sciences, has commenced with the dosing of the first participant.

Indaptus Therapeutics has reported encouraging outcomes from the second group of participants in its Phase 1 clinical trial for a drug candidate called Decoy20.

A new formulation of an HIV drug, cabotegravir ultra long-acting (CAB-ULA), has demonstrated the potential for dosing intervals of at least four months.

Revelation Biosciences has initiated a Phase 1 clinical trial for its proprietary compound Gemini, which is designed to leverage trained immunity for disease prevention and treatment.

In the realm of clinical research, obtaining patient consent for trials is a critical step that ensures participants are well-informed and willingly engage in the study.

FSD Pharma presented findings from a Phase-1 clinical trial of its compound Lucid-21-302, intended for the treatment of Multiple Sclerosis (MS).

Exonate‘s flagship product, EXN407, is a topical SRPK1 inhibitor that has shown promising results in both safety and effectiveness as a monotherapy for conditions like diabetic retinopathy and diabetic macular oedema.

The occasion aimed to showcase preliminary data from Phase 1 trials of their innovative small molecule-drug conjugate (SMDC), VIP236.

Avacta Group plc announced that updated results from their Phase 1 clinical trial of the peptide drug conjugate AVA6000 were presented at the AACR.

This collaboration aims to advance the Phase I/II clinical trials of TG4050, a personalized therapeutic vaccine for patients afflicted with head and neck cancers.